SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

IL17A-IN-1

Cat. No.:	HY-158159
Molecular Formula:	$C_{30}H_{35}Cl_2N_7O_3$
Molecular Weight:	612.55
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer[1].

In Vitro

IL17A-IN-1 inhibits Hela cells with an IC_{50} value of 0.005 μM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

IL17A-IN-1 (10 mg/kg; p.o.; single dose) inhibits plasma CXCL1 secretion in hIL17A-induced mouse (IL17 receptor-containing mouse) CXCL1 PD model[1]. (Subcutaneous injection of recombinant human IL17A into mice induces plasma CXCL1 secretion).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (hIL17A-induced mouse CXCL1 PD model)[1].
Dosage:	10 mg/kg
Administration:	Oral administration; single dose
Result:	Inhibited 53% of CXCL1 secretion in hIL17A-induced mouse CXCL1 PD model.

Animal Model:	Male Sprague-Dawley rats; 360-460 g[1].
Dosage:	0.3 mg/kg
Administration:	Intravenous injection; single dose
Result:	Pharmacokinetic Parameters of IL17A-IN-1 in male Sprague-Dawley rats[1].

	IV (0.3 mg/kg)
V_{ss} (L/kg)	5.0

	$t_{1/2}$ (h)	3.6
	CLp/CLp,u (L/h/kg)	1.1/6.1

REFERENCES

[1]. Ramos AL, et al. Discovery of Small Molecule Interleukin 17A Inhibitors with Novel Binding Mode and Stoichiometry: Optimization of DNA-Encoded Chemical Library Hits to In Vivo Active Compounds. J Med Chem. 2024 Apr 4.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA